Moolec Science SA Dossier - Source-backed chat

Moolec Science SA

MLECNASDAQ

SectorConsumer Staples

IndustryFood Products

Beta (adjusted)0.48

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.81Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $3.5M

Enterprise Value $16.3M

Shares Outstanding 726.1K diluted

Next Earnings Date2 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Moolec Science SA (NASDAQ: MLEC) is a pioneer in Molecular Farming, successfully expressing animal proteins (such as bovine myoglobin in pea seeds) and high-value nutritional lipids (GLASO1 safflower platform) in crops. While the company has achieved significant scientific breakthroughs and recently regained compliance with Nasdaq's continued listing requirements, it remains in an early commercialization phase with high capital requirements and historical volatility. The transition from R&D to full-scale commercial deployment warrants a cautious Hold stance until consistent revenue generation and market adoption are demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Agronomic failures, crop yield shortfalls, or delays in commercialization of the 2026 campaign strain liquidity. Failure to maintain the minimum stockholders' equity standard triggers renewed Nasdaq delisting warnings, forcing dilutive capital raises.

Base CaseCentral scenario

The company successfully scales its GLASO1 safflower platform through the 2026 campaign, leveraging its Idaho-based agricultural footprint. It maintains Nasdaq compliance and gradually converts its remaining preference shares to bolster stockholders' equity, while advancing its bovine myoglobin pea platform toward commercial viability.

Bull CaseUpside scenario

Moolec Science's bull case centers on its pioneering Molecular Farming technology, specifically its patented 'Piggy Sooy' platform (genetically engineered soybeans producing high levels of porcine hemeproteins) and GLASO (safflower oil containing high levels of GLA). The USDA-APHIS has cleared Piggy Sooy from key regulatory hurdles, and the company holds exclusive commercial rights in the U.S. until 2042. Successful FDA consultation and commercialization of these animal-free proteins could disrupt the alternative protein and food ingredient markets, offering massive upside.

Scenarios reflect our research view at the research date.

Key Investment Merits

Pioneering Molecular Farming technology that combines the cost efficiency of traditional crops with the functionality of animal proteins.
Successful commercial-scale validation of the GLASO1 platform, achieving a 45% GLA concentration.
First-of-its-kind scientific breakthrough in expressing bovine myoglobin in pea seeds.
Strong intellectual property portfolio with over 50 granted patents and patent applications.

Key Investment Risks

High operational cash burn and reliance on capital-strengthening measures (such as preference share conversions) to maintain Nasdaq compliance.
Agricultural and agronomic risks, including weather, soil preparation, and crop emergence variables in commercial planting campaigns.
Regulatory hurdles associated with genetically modified crops and novel food ingredients in global markets.

Thesis Invalidation Triggers

Failure to maintain Nasdaq Capital Market listing requirements.
Severe crop yield shortfalls in the 2026 GLASO1 commercial campaign.
Inability to secure commercial offtake agreements for plant-grown products.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.